| P50 | author | Karen-Sue B Carlson | Q38325067 |
| | Joseph M. Scandura | Q37382335 |
| P2093 | author name string | Paul J Christos | |
| | Eric J Feldman | |
| | Gail J Roboz | |
| | Cindy Ippoliti | |
| | Ellen K Ritchie | |
| | Catherine B Lagassa | |
| | Sarah D Rohan | |
| P2860 | cites work | Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities | Q37480178 |
| | Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia | Q40408341 |
| | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 |
| | Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial | Q43206160 |
| | Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome | Q82366072 |
| | A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study | Q83434939 |
| | Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group | Q27851459 |
| | Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | Q33401766 |
| | Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine | Q33841988 |
| | Treatment of relapsed and refractory acute myelogenous leukemia | Q33864571 |
| | Age and acute myeloid leukemia | Q34564663 |
| | Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia | Q34615081 |
| | A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy | Q35794439 |
| | Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia | Q36057877 |
| | Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia | Q36445921 |
| | Are low-intensity induction strategies better for older patients with acute myeloid leukemia? | Q36765059 |
| | Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide | Q37201853 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| | leukemia | Q29496 |
| P304 | page(s) | 2003-2007 | |
| P577 | publication date | 2013-02-07 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia | |
| P478 | volume | 54 | |